Vikram Verghese Sells 5,876 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 5,876 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $50.60, for a total transaction of $297,325.60. Following the transaction, the chief financial officer owned 248,683 shares of the company’s stock, valued at $12,583,359.80. This represents a 2.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

• On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The shares were sold at an average price of $49.69, for a total transaction of $1,368,462.60.

Heartflow Trading Down 1.6%

Shares of HTFL stock opened at $48.91 on Friday. The firm’s 50 day moving average is $33.76 and its 200 day moving average is $29.92. The stock has a market capitalization of $4.25 billion and a P/E ratio of -26.73. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $51.78.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. On average, equities analysts predict that Heartflow, Inc. will post -0.75 EPS for the current year.

Hedge Funds Weigh In On Heartflow

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HTFL. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Heartflow in the 4th quarter valued at about $27,000. Russell Investments Group Ltd. bought a new position in shares of Heartflow in the fourth quarter worth approximately $45,000. Essential Partners LLC purchased a new stake in Heartflow in the first quarter valued at approximately $57,000. Legal & General Group Plc purchased a new stake in Heartflow in the third quarter valued at approximately $59,000. Finally, Strs Ohio bought a new stake in Heartflow during the fourth quarter valued at approximately $99,000.

Analyst Upgrades and Downgrades

HTFL has been the topic of a number of recent research reports. Wells Fargo & Company increased their price objective on Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Stifel Nicolaus upped their price target on Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Piper Sandler reissued an “overweight” rating and issued a $45.00 price target (up from $38.00) on shares of Heartflow in a report on Friday, August 14th. Morgan Stanley raised their price objective on shares of Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. Finally, Weiss Ratings raised shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.43.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.